查看購物車
  • Simplified Chinese
  • English
  • Japanese
歐洲生物製劑藥物研發市場：按製造商、類型和國家分類的分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1892734

歐洲生物製劑藥物研發市場：按製造商、類型和國家分類的分析和預測（2025-2035 年）

Europe Biologics Drug Discovery Market: Focus on Manufacturing Type, Type, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 81 Pages | 商品交期: 1-5個工作天內

價格

歐洲生物製劑藥物研發市場預計將從 2024 年的 64.3 億美元成長到 2035 年的 171.6 億美元，在預測期（2025-2035 年）內以 9.36% 的複合年成長率成長。

市場成長主要受罕見疾病和慢性病患者增多以及對精準標靶治療需求不斷成長的推動。生物製劑，包括單株抗體、重組蛋白以及新一代治療方法的研發，因其優於傳統小分子療法的療效、安全性和選擇性，在全部區域日益普及。神經病學、免疫學和腫瘤學等關鍵治療領域的進展，得益於歐洲強大的創新生態系統，以及政府資助的研究計畫、產學合作和不斷完善的監管指南的支持。

關鍵市場統計數據
預測期 2025-2035
2025 年評估 70.1億美元
2035 年預測 171.6億美元
複合年成長率 9.36%

技術進步正進一步提升該地區的藥物研發能力。高通量篩檢、多組體學整合、人工智慧輔助標靶選擇以及先進的抗體設計平台，在提高早期研發效率的同時，也增加了臨床成功的幾率。然而，該產業仍面臨許多結構性挑戰，包括研發成本高昂、生物製劑生產流程複雜以及歐洲各國在研發能力和熟練勞動力方面的差距。但隨著投資的增加、外包給專業合約研究組織（CRO）和合約研發生產機構（CDMO）的趨勢日益明顯，以及個人化醫療的興起，歐洲已做好充分準備，在引領生物製劑發展方向和下一代治療創新方面發揮關鍵作用。

市場概覽

在快速的科學進步、不斷變化的治療需求以及全部區域強勁的投資活動的推動下，歐洲生物製劑藥物研發市場正經歷變革時期。隨著生物製劑不斷展現出超越傳統小分子藥物的臨床成功和商業性價值，歐洲已成為先進藥物研發平台、抗體工程、細胞和基因治療研究以及RNA療法和多特異性抗體等新一代療法的關鍵中心。

人口老化、慢性病盛行率上升以及對個人化和標靶治療日益成長的需求，使得高價值生物製劑在該地區的重要性更加凸顯。製藥公司、生技新興企業、合約研究組織 (CRO) 和合約研發開發機構 (CDMO) 之間的合作正在不斷擴大，以加速藥物發現、最佳化先導化合物並儘早識別出有效成分。早期研究正因數位技術的變革而轉變，尤其是人工智慧驅動的蛋白質設計、In Silico模擬和數據驅動的生物標記識別。

同時，歐洲監管環境的變化，特別是新的歐盟衛生技術評估（HTA）框架，正迫使研發人員在研發早期階段就提供更多比較性證據和真實世界證據（RWE）。雖然這增加了研發的複雜性，但也有助於確保高品質的創新，並加速創新治療方法的應用。總體而言，歐洲正透過將卓越的科學實力與不斷擴大的研發和商業化合作夥伴網路相結合，鞏固其在生物製劑發現領域的全球領先地位。

市場區隔:

細分 1：依生產類型

  • 內部生產
  • 外包委託製造

細分 2：按類型

  • 單株抗體
  • 重組蛋白
  • 其他生物製劑

細分3：按地區

  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他

本報告調查了歐洲生物製劑藥物發現市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章 歐洲生物製劑藥物研發市場：產業展望

  • 市場概覽
  • 主要市場趨勢
    • 雙特異性和多特異性抗體研發進展
    • 加強夥伴關係與合作
    • 對外包服務的需求不斷成長
  • 監管狀態
    • 歐洲
  • 供應鏈分析
    • 供應鍊及其風險
  • 市場動態
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章：生物製劑藥物研發市場（依地區分）

  • 歐洲
    • 區域概覽
    • 市場成長促進因素
    • 市場問題
    • 市場規模及預測

第3章 競爭基準化分析與公司概況

  • 各公司的主要策略和發展
  • 公司簡介
    • AstraZeneca Plc
    • Evotec SE
    • F. Hoffmann-La Roche AG
    • Merck KGaA
    • Novo Nordisk A/S
    • Novartis AG

第4章調查方法

Product Code: BHP3491SS

This report can be delivered in 2 working days.

Introduction to Europe Biologics Drug Discovery Market

The Europe biologics drug discovery market is projected to reach $17.16 billion by 2035 from $6.43 billion in 2024, growing at a CAGR of 9.36% during the forecast period 2025-2035. The increasing prevalence of uncommon and chronic diseases as well as the growing need for precision-targeted treatments are driving the biologics drug discovery industry in Europe. Due to their superior therapeutic effects, greater safety profiles, and increased selectivity as compared to traditional small-molecule treatments, biologics-which include monoclonal antibodies, recombinant proteins, and developing next-generation modalities-are becoming more and more popular throughout the region. Developments in important therapeutic fields like neurology, immunology, and oncology are being accelerated by Europe's robust innovation ecosystem, which is supported by government-funded research programs, academic-industry collaborations, and changing regulatory guidelines.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$7.01 Billion
2035 Forecast$17.16 Billion
CAGR9.36%

Technological developments are improving the area's capacity for discovery even more. High-throughput screening, multi-omics integration, AI-enabled target selection, and advanced antibody-engineering platforms are raising the likelihood of clinical success and enhancing early-stage efficiency. High R&D expenses, complicated biologics manufacturing, and differences in research capacity and skilled labor among European nations are some of the structural issues that the sector still faces. Nevertheless, Europe is positioned to play a major role in determining the direction of biologics drug development and next-generation therapeutic innovation due to growing investments, increased outsourcing to specialized CROs and CDMOs, and a growing shift toward personalized medicine.

Market Introduction

The Europe biologics drug discovery market is undergoing a transitional period, propelled by swift scientific advancements, changing therapeutic requirements, and robust investment activity throughout the area. Europe has become a vital center for advanced discovery platforms, antibody engineering, cell and gene therapy research, and next-generation modalities like RNA therapeutics and multispecific antibodies as biologics continue to surpass conventional small-molecule drugs in clinical success and commercial value.

The region's emphasis on high-value biologics is being strengthened by aging populations, an increase in the prevalence of chronic diseases, and a growing need for tailored, targeted treatments. Collaborations between pharmaceutical corporations, biotech startups, CROs, and CDMOs are growing in order to expedite translational development, optimize lead candidates, and speed up hit identification. Early-stage research is being transformed by digital technologies, particularly AI-driven protein design, in silico modeling, and data-driven biomarker identification.

At the same time, Europe's changing regulatory landscape, especially the new EU HTA framework, is requiring developers to create more comparative and real-world evidence earlier in the pipeline. Although this makes things more complicated, it also guarantees excellent innovation and quicker adoption of ground-breaking treatments. All things considered, Europe is establishing itself as a world leader in biologics discovery by fusing scientific brilliance with an expanding network of research and commercialization partners.

Market Segmentation:

Segmentation 1: By Manufacturing Type

  • In-House Manufacturing
  • Outsourced Manufacturing

Segmentation 2: By Type

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Other Biologics

Segmentation 3: By Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Europe Biologics Drug Discovery Market Trends, Drivers and Challenges

Market Trends

  • Strong expansion of biologics as one of Europe's fastest-growing pharmaceutical segments.
  • Shift toward advanced modalities such as cell and gene therapies, RNA therapeutics, multispecifics, and ADCs.
  • Rising integration of AI, machine learning, and computational protein design to accelerate early-stage discovery.
  • Increased partnerships, licensing deals, and outsourcing to CROs/CDMOs for specialized discovery capabilities.
  • Growing biosimilar development influencing portfolio decisions and lifecycle management.

Market Growth Drivers

  • Advancements in high-throughput screening, single-cell analysis, and structural biology speeding up target validation.
  • Ageing population and rising prevalence of chronic and rare diseases boosting demand for innovative biologics.
  • Strong investment inflow from pharma, biotech, VC, and strategic collaborations supporting R&D.
  • Supportive innovation initiatives and evolving regulatory frameworks encouraging advanced biologics.
  • Increasing use of real-world data and digital platforms for biomarker research and target selection.

Market Challenges

  • Complex and fragmented regulatory and HTA pathways across Europe affecting approval and access timelines.
  • Intensifying pricing pressure and reimbursement hurdles due to payer scrutiny and biosimilar competition.
  • High manufacturing and CMC complexity leading to elevated development costs and longer timelines.
  • Talent shortage in specialized areas like protein engineering, biologics CMC, and regulatory sciences.
  • Supply-chain vulnerabilities linked to dependence on external regions for APIs and CDMO capacity.

How can this report add value to an organization?

Product/Innovation Strategy: The Europe biologics drug discovery market has been extensively segmented based on various categories, such as manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments.

Competitive Strategy: The Europe biologics drug discovery market has numerous established players with product portfolios. Key players in the Europe biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • AstraZeneca Plc
  • Evotec SE
  • Merck KGaA
  • Novo Nordisk A/S
  • Novartis AG
  • F. Hoffmann-La Roche AG

Table of Contents

Executive Summary

Scope and Definition

1 Europe Biologics Drug Discovery Market: Industry Outlook

  • 1.1 Market Overview
  • 1.2 Key Market Trends
    • 1.2.1 Growth of Bispecific and Multispecific Antibody Development
    • 1.2.2 Rising Partnerships and Collaborations
    • 1.2.3 Rising Demand for Outsourcing Services
  • 1.3 Regulatory Landscape
    • 1.3.1 Europe
      • 1.3.1.1 Germany
      • 1.3.1.2 France
      • 1.3.1.3 Italy
  • 1.4 Supply Chain Analysis
    • 1.4.1 Supply Chain and Risks within the Supply Chain
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
      • 1.5.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
    • 1.5.2 Market Challenges
      • 1.5.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
    • 1.5.3 Market Opportunities
      • 1.5.3.1 AI Integration in Biologics Discovery

2 Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035

  • 2.1 Europe
    • 2.1.1 Regional Overview
    • 2.1.2 Driving Factors for Market Growth
    • 2.1.3 Factors Challenging the Market
    • 2.1.4 Market Sizing and Forecast
      • 2.1.4.1 Europe Biologics Drug Discovery Market, by Manufacturing Type
      • 2.1.4.2 Europe Biologics Drug Discovery Market, by Type
      • 2.1.4.3 Europe Biologics Drug Discovery Market, by Country
        • 2.1.4.3.1 Germany
          • 2.1.4.3.1.1 Country Overview
          • 2.1.4.3.1.2 Driving Factors for Market Growth
          • 2.1.4.3.1.3 Factors Challenging the Market
          • 2.1.4.3.1.4 Market Sizing and Forecast
          • 2.1.4.3.1.4.1 Germany Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.1.4.2 Germany Biologics Drug Discovery Market, by Type
        • 2.1.4.3.2 U.K.
          • 2.1.4.3.2.1 Country Overview
          • 2.1.4.3.2.2 Driving Factors for Market Growth
          • 2.1.4.3.2.3 Factors Challenging the Market
          • 2.1.4.3.2.4 Market Sizing and Forecast
          • 2.1.4.3.2.4.1 U.K. Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.2.4.2 U.K. Biologics Drug Discovery Market, by Type
        • 2.1.4.3.3 France
          • 2.1.4.3.3.1 Country Overview
          • 2.1.4.3.3.2 Driving Factors for Market Growth
          • 2.1.4.3.3.3 Factors Challenging the Market
          • 2.1.4.3.3.4 Market Sizing and Forecast
          • 2.1.4.3.3.4.1 France Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.3.4.2 France Biologics Drug Discovery Market, by Type
        • 2.1.4.3.4 Italy
          • 2.1.4.3.4.1 Country Overview
          • 2.1.4.3.4.2 Driving Factors for Market Growth
          • 2.1.4.3.4.3 Factors Challenging the Market
          • 2.1.4.3.4.4 Market Sizing and Forecast
          • 2.1.4.3.4.4.1 Italy Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.4.4.2 Italy Biologics Drug Discovery Market, by Type
        • 2.1.4.3.5 Spain
          • 2.1.4.3.5.1 Country Overview
          • 2.1.4.3.5.2 Driving Factors for Market Growth
          • 2.1.4.3.5.3 Factors Challenging the Market
          • 2.1.4.3.5.4 Market Sizing and Forecast
          • 2.1.4.3.5.4.1 Spain Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.5.4.2 Spain Biologics Drug Discovery Market, by Type
        • 2.1.4.3.6 Rest-of-Europe
          • 2.1.4.3.6.1 Country Overview
          • 2.1.4.3.6.2 Driving Factors for Market Growth
          • 2.1.4.3.6.3 Factors Challenging the Market
          • 2.1.4.3.6.4 Market Sizing and Forecast
          • 2.1.4.3.6.4.1 Rest-of-Europe Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.6.4.2 Rest-of-Europe Biologics Drug Discovery Market, by Type

3 Competitive Benchmarking and Company Profiles

  • 3.1 Key Strategies and Developments by Company
    • 3.1.1 Funding Activities
    • 3.1.2 Mergers and Acquisitions
    • 3.1.3 Regulatory Approvals and Product Launches
    • 3.1.4 Partnerships, Collaborations, and Business Expansions
  • 3.2 Company Profiles
    • 3.2.1 AstraZeneca Plc
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products/Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personal
      • 3.2.1.6 Analyst View
    • 3.2.2 Evotec SE
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personal
      • 3.2.2.6 Analyst View
    • 3.2.3 F. Hoffmann-La Roche AG
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personal
      • 3.2.3.6 Analyst View
    • 3.2.4 Merck KGaA
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products/Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers
      • 3.2.4.5 Key Personal
      • 3.2.4.6 Analyst View
    • 3.2.5 Novo Nordisk A/S
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products/Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers
      • 3.2.5.5 Key Personal
      • 3.2.5.6 Analyst View
    • 3.2.6 Novartis AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products/Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers
      • 3.2.6.5 Key Personal
      • 3.2.6.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Europe Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
  • Figure 2: Europe Biologics Drug Discovery Market, 2024 and 2035
  • Figure 3: Biologics Drug Discovery Market, $Billion, 2025 and 2035
  • Figure 4: Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
  • Figure 5: Europe Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
  • Figure 6: Incidence of Cancer (by Region), 2020-2040
  • Figure 7: Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 8: Germany Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 9: U.K. Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 10: France Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 11: Italy Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 12: Spain Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 13: Rest-of-Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 14: Data Triangulation
  • Figure 15: Top-Down and Bottom-Up Approach
  • Figure 16: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Europe Biologics Drug Discovery Market, Key Market Trends
  • Table 3: Key Partnerships in the Biologics Drug Discovery Market
  • Table 4: Market Dynamics
  • Table 5: Biologics Drug Discovery Market (by Region), $Billion, 2023-2035
  • Table 6: Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 7: Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 8: Europe Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 9: Germany Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 10: Germany Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 11: U.K. Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 12: U.K. Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 13: France Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 14: France Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 15: Italy Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 16: Italy Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 17: Spain Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 18: Spain Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 19: Rest-of-Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 20: Rest-of-Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 21: Some of the Major Key Strategies: Funding Activities, January 2022 - September 2025
  • Table 22: Some of the Major Key Strategies: Mergers and Acquisitions, January 2022 - September 2025
  • Table 23: Some of the Major Key Strategies: Regulatory Approvals and Product Launches, January 2022 - September 2025
  • Table 24: Some of the Major Key Strategies: Partnerships, Collaborations, and Business Expansions, January 2022 - September 2025